Trial Information
Quality of Life Analysis of Prostate Cancer Patient's Therapy
Inclusion Criteria:
- Provision of informed consent
- Early or locally-advanced prostate cancer patients on androgen deprivation therapy
- Investigators are requested to recruit patients only with at least 1 month prior
Zoladex treatment.
Exclusion Criteria:
- Allergy to substance of medication
- Prostate cancer patients with advanced disease
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Elements of a general and three disease-specific investigator questionnaire
Outcome Time Frame:
Quarterly (plus or minus 3 days )
Safety Issue:
No
Principal Investigator
Péter Tenke, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
"Jahn Ferenc" City Hospital Budapest
Authority:
Hungary: National Institute of Pharmacy
Study ID:
NIS-OHU-ZOL-2007/1
NCT ID:
NCT00692874
Start Date:
June 2008
Completion Date:
September 2010
Related Keywords:
- Prostate Cancer
- Quality of Life
- Prostatic Neoplasms